Stockscreener 앱 받기
0.39
0.00%
0.00
전일 마감가:
$0.39
열려 있는:
$0.498
하루 거래량:
55,086
Relative Volume:
33.01
시가총액:
$N/A
수익:
-
순이익/손실:
$-37.07M
주가수익비율:
-0.5652
EPS:
-0.69
순현금흐름:
$-23.91M
1주 성능:
-6.25%
1개월 성능:
-62.57%
6개월 성능:
-97.12%
1년 성능:
-95.25%
1일 변동 폭
$0.37
$0.498
1주일 범위
$0.37
$0.498
52주 변동 폭
$0.37
$0.498
실로스 테라 Stock (SEEL) Company Profile
SEEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SEEL | 0.39 | 0 | 0 | -37.07M | -23.91M | -0.69 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
실로스 테라 Stock (SEEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-27 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-07-01 | 개시 | Guggenheim | Buy |
| 2021-06-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-17 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-03-30 | 개시 | B. Riley Securities | Buy |
| 2019-11-14 | 개시 | The Benchmark Company | Speculative Buy |
| 2019-05-14 | 개시 | ROTH Capital | Buy |
모두보기
실로스 테라 주식(SEEL)의 최신 뉴스
Biopharm Co. Seelos Files For Ch. 11 After Nasdaq Delisting - Law360
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock - Quantisnow
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split - GuruFocus.com
Seelos Announces Postponement of its Annual Meeting of Stockholders - GuruFocus.com
SEELOS THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Seelos Therapeutics announces the signing of a Material Transfer - GuruFocus.com
Seelos Announces Second Postponement of its Annual Meeting of Stockholders - StockTitan
Seelos Therapeutics (NASDAQ:SEEL) and Zoetis (NYSE:ZTS) Head-To-Head Contrast - Defense World
SEEL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Closing Bell Recap: Seelos Therapeutics Inc (SEEL) Ends at 1.28, Reflecting a -47.76 Downturn - The Dwinnex
Seelos Therapeutics Delisted From Nasdaq, Will Transition To OTC Market - Benzinga
Seelos gets Nasdaq delisting notice - MSN
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - Morningstar
SEEL stock touches 52-week low at $2.37 amid market challenges By Investing.com - Investing.com South Africa
SEEL stock touches 52-week low at $2.37 amid market challenges - Investing.com
Seelos Therapeutics Inc (SEEL) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Financial Health Check: Examining Seelos Therapeutics Inc (SEEL)’s Key Ratios - The Dwinnex
Seelos Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Seelos Therapeutics faces Nasdaq delisting over share price - Investing.com
SEEL stock touches 52-week low at $2.77 amid market challenges By Investing.com - Investing.com South Africa
SEEL stock touches 52-week low at $2.77 amid market challenges - Investing.com Australia
Was Seelos Therapeutics Inc (SEEL)’s session last reading good? - US Post News
SEEL’s Financial Health: Exploring Seelos Therapeutics Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected - Benzinga
Seelos Therapeutics approves reverse stock split By Investing.com - Investing.com South Africa
Seelos Therapeutics approves reverse stock split - Investing.com India
Seelos Therapeutics Announces Reverse Stock Split and Adjustments - TipRanks
Seelos Therapeutics to execute 1-for-16 reverse stock split - MSN
Taking the lead: Seelos Therapeutics Inc (SEEL) - SETE News
Investing in Seelos Therapeutics Inc (SEEL): What You Must Know - Knox Daily
Seelos Therapeutics announces 1-for-16 reverse stock split - TipRanks
3 Penny Stocks to Watch Now, 9/25/24 - TipRanks
Seelos to supply PTSD treatment for U.S. Army trial By Investing.com - Investing.com Australia
Seelos Therapeutics, Inc. (SEEL): A Strategic Move with SLS-002 in the Fight Against PTSD - BP Journal
Biotech Soars On Material Transfer Agreement - MSN
What's Going On With Seelos Therapeutics Stock Tuesday? - MSN
Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity - Marketscreener.com
TSX Composite Dividend Index (TXDC) QuotePress Release - The Globe and Mail
TSX Composite Banks Index (TXBA) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Dow Futures Mini (YMH19) Quote - The Globe and Mail
Seelos Therapeutics Inc Inc. (SEEL) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Crude Oil Gains Over 1%; BioVie Shares Plunge - Benzinga
Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug - XM
Seelos to supply PTSD treatment for U.S. Army trial - Investing.com India
Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD - PR Newswire
"Nasdaq Stocks Set for Explosive Growth: BNZI, SEEL, PRSO, MSS, HSCS Revamp for Big Potential" - openPR
What to expect from Esperion Therapeutics Inc.’s (ESPR) current quarter earnings? - US Post News
Integral Health Asset Management LLC Has $6.39 Million Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO) - Defense World
Beck Capital Management LLC Reduces Stock Holdings in MercadoLibre, Inc. (NASDAQ:MELI) - Defense World
Is Seelos Therapeutics Inc (SEEL) worth investing in despite its undervalued state? - US Post News
실로스 테라 (SEEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):